| Hypertensive disease

Bystolic vs Katerzia

Side-by-side clinical, coverage, and cost comparison for hypertensive disease.

Deep comparison between: Bystolic vs Katerzia with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsKaterzia has a higher rate of injection site reactions vs Bystolic based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Katerzia but not Bystolic, including UnitedHealthcare

Category

Bystolic

Katerzia

At A Glance

RouteOral

FrequencyDaily

ClassSelective beta-1 blocker

RouteOral

FrequencyDaily

ClassCalcium channel blocker

Indications

Hypertensive disease

Hypertensive disease
Stable angina
Angina Pectoris, Variant
Coronary Artery Disease

Dosing

Hypertensive disease Start at 5 mg once daily, with or without food; increase at 2-week intervals up to 40 mg. In severe renal impairment (ClCr <30 mL/min), start at 2.5 mg once daily. In moderate hepatic impairment (Child-Pugh Class B), start at 2.5 mg once daily.

Hypertensive disease (adults) 5 mg orally once daily (max 10 mg); start 2.5 mg in small, fragile, elderly patients, or those with hepatic insufficiency.

Hypertensive disease (pediatric, ages 6-17) 2.5-5 mg orally once daily; doses >5 mg have not been studied in pediatric patients.

Stable angina, Angina Pectoris, Variant 5-10 mg orally once daily; lower dose suggested in elderly and patients with hepatic insufficiency; most patients require 10 mg.

Coronary Artery Disease 5-10 mg orally once daily; majority of patients required 10 mg in clinical studies.

Contraindications

Severe bradycardia
Heart block greater than first degree
Cardiogenic shock
Decompensated cardiac failure
Sick sinus syndrome (unless a permanent pacemaker is in place)
Severe hepatic impairment (Child-Pugh >B)
Hypersensitivity to any component of this product

Known sensitivity to amlodipine

Drug Interactions

1190View drug interactions

1162View drug interactions

Adverse Reactions

Most common (>=1%) Headache, fatigue, diarrhea, nausea, dizziness, bradycardia, chest pain, peripheral edema, insomnia, dyspnea, rash

Postmarketing Abnormal hepatic function, acute pulmonary edema, acute renal failure, atrioventricular block (second and third degree), bronchospasm, erectile dysfunction, hypersensitivity (urticaria, allergic vasculitis, angioedema), hypotension, myocardial infarction, pruritus, psoriasis, Raynaud's phenomenon, peripheral ischemia/claudication, somnolence, syncope, thrombocytopenia, vertigo, vomiting

Most common (>1%) edema, dizziness, flushing, palpitation, fatigue, nausea, abdominal pain, somnolence

Postmarketing gynecomastia, jaundice, hepatic enzyme elevations, extrapyramidal disorder

Pharmacology

Nebivolol is a beta-adrenergic receptor blocking agent; at doses <=10 mg in extensive metabolizers it is preferentially beta1-selective, while in poor metabolizers or at higher doses it inhibits both beta1- and beta2-adrenergic receptors, lacking intrinsic sympathomimetic and membrane-stabilizing activity at therapeutically relevant concentrations.

Amlodipine is a dihydropyridine calcium channel blocker that inhibits transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, causing peripheral arterial vasodilation, reduction in peripheral vascular resistance, and reduction in blood pressure.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Bystolic